Effects of dopaminergic compounds on carbonic anhydrase isozymes I, II, and VI

Figures & data

Table 1.  hCA I, II and VI inhibition data with compounds 3–6, 10–11 and acetazolamide (AZA), by an esterase assay with 4-nitrophenylacetate as substrate

Compound	Ki (μM)
	hCA I	hCA II	hCA VI
3	41.1	0.44	1.15
4	45.1	0.38	0.97
5	363	470	0.78
6	161	143	0.58
10^a	309	11.2	nt
11^a	237	131	nt
AZA	36.4	0.42	0.048

Mean from at least three determinations. Errors in the range of 3–8% of the reported value (data not shown).

^aFrom ref. (³²).

Scheme 1.  Dopaminergic compounds investigated in the present study.

Table 2.  hCA I, II and VI activation data with compounds 1 and 7–9³¹

Compound	KA (μM)*
	hCA I	hCA II	hCA VI
Dopamine 1	13.5	9.2	21
7	27.3	18.4	8.7
Serotonin 8	45	50	19
L-Trp 9	44	27	15

*Mean from at least three determinations. Errors in the range of 5–10% of the reported value (data not shown).

Ilies M, Scozzafava A, Supuran CT. Carbonic anhydrase activators. In Carbonic anhydrase – Its inhibitors and activators; Supuran CT, Scozzafava A, Conway J, Eds.; CRC Press: Boca Raton (FL), USA, 2004; p 317.

 Google Scholar

Vullo D, Innocenti A, Nishimori I, Scozzafava A, Kaila K, Supuran CT. Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. Bioorg Med Chem Lett 2007;17:4107–4112.

 PubMed Web of Science ®Google Scholar